BIOR Insider Trading Activity and SEC Form 4 Filings
BIOR insider trading summary
No open-market insider purchases or sales of Biora Therapeutics, Inc. (BIOR) have been reported on SEC Form 4 in the past 12 months.
Latest BIOR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Nov 9, 2022 | Athyrium Funds GP Holdings LLC | 10% Owner | Buy | $0 (12,506,250 @ $0.00) |
| Nov 9, 2022 | Athyrium Opportunities Associates Co-Invest LLC | 10% Owner | Buy | $0 (12,506,250 @ $0.00) |
| Nov 9, 2022 | Athyrium Opportunities III Co-Invest 1 LP | 10% Owner | Buy | $0 (12,506,250 @ $0.00) |
| Nov 9, 2022 | Athyrium Opportunities III Acquisition 2 LP | 10% Owner | Buy | $0 (12,506,250 @ $0.00) |
| Nov 9, 2022 | Jeffrey Ferrell | Director | Buy | $0 (12,506,250 @ $0.00) |
| Nov 9, 2022 | Athyrium Opportunities III Acquisition LP | 10% Owner | Buy | $0 (12,506,250 @ $0.00) |
| Nov 9, 2022 | Athyrium Opportunities 2020 LP | 10% Owner | Buy | $0 (12,506,250 @ $0.00) |
| Nov 9, 2022 | Athyrium Opportunities Associates III GP LLC | 10% Owner | Buy | $0 (12,506,250 @ $0.00) |
| Nov 9, 2022 | Athyrium Opportunities Associates III LP | 10% Owner | Buy | $0 (12,506,250 @ $0.00) |
| Jul 5, 2022 | Surbhi Sarna | Director | Sell | $5K (7,517 @ $0.61) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.